New and recently funded Medical Startups
1
Country: USA | Funding: $4.3B
Revolution Medicines develops novel treatments for cancers associated with RAS activation (which accounts for 30 percent of all new human cancer diagnoses). The company is building a portfolio of RAS(ON) inhibitors using its tricomplex inhibitor platform, which provides unprecedented access to the active form of oncogenic RAS. Revolution Medicines is building a comprehensive pipeline of targeted therapies for the discovery, development, and delivery of new therapeutic options for PDAC, NSCLC, and solid tumors. The pipeline is designed to allow the evaluation of compounds as monotherapies and in combination with existing standard-of-care therapies and/or other compounds within our portfolio.
Revolution Medicines develops novel treatments for cancers associated with RAS activation (which accounts for 30 percent of all new human cancer diagnoses). The company is building a portfolio of RAS(ON) inhibitors using its tricomplex inhibitor platform, which provides unprecedented access to the active form of oncogenic RAS. Revolution Medicines is building a comprehensive pipeline of targeted therapies for the discovery, development, and delivery of new therapeutic options for PDAC, NSCLC, and solid tumors. The pipeline is designed to allow the evaluation of compounds as monotherapies and in combination with existing standard-of-care therapies and/or other compounds within our portfolio.
2
Country: USA | Funding: $1.1B
Click Therapeutics is looking to boost work on an online platform of “prescription digital therapeutics.” The company’s leading product is Clickotine, deisgned for smoking cessation, that works as a phone app designed to help people stop smoking using input from Magellan Health, a behavioral healthcare company.
Click Therapeutics is looking to boost work on an online platform of “prescription digital therapeutics.” The company’s leading product is Clickotine, deisgned for smoking cessation, that works as a phone app designed to help people stop smoking using input from Magellan Health, a behavioral healthcare company.
3
Country: France | Funding: $219.7M
Enterome develops breakthrough immunomodulatory drugs for cancer treatment – OncoMimics peptides – based on the interaction between the gut microbiome and the immune system. The company's candidates target a wide range of tumor types (glioblastoma, adrenal tumors, non-Hodgkin's lymphoma, and colorectal cancer). OncoMimics are a specific combination of bacterial peptides derived from bacteria present in the gut microbiome that precisely mimic either overexpressed tumor-associated antigens or specific markers in solid and liquid tumors, respectively. The company has developed a drug discovery platform that enables the analysis of the world's largest microbiome protein database and the creation of new drugs.
Enterome develops breakthrough immunomodulatory drugs for cancer treatment – OncoMimics peptides – based on the interaction between the gut microbiome and the immune system. The company's candidates target a wide range of tumor types (glioblastoma, adrenal tumors, non-Hodgkin's lymphoma, and colorectal cancer). OncoMimics are a specific combination of bacterial peptides derived from bacteria present in the gut microbiome that precisely mimic either overexpressed tumor-associated antigens or specific markers in solid and liquid tumors, respectively. The company has developed a drug discovery platform that enables the analysis of the world's largest microbiome protein database and the creation of new drugs.
4
Country: USA | Funding: $22M
Keebler Health is a developer of an AI-based risk adjustment tool for healthcare providers.
Keebler Health is a developer of an AI-based risk adjustment tool for healthcare providers.
5
Country: USA | Funding: $125.4M
Calyxo has developed the CVAC surgical system for kidney stone removal and the corresponding procedure called SURE. The company's device utilizes irrigation and vacuum aspiration during and after laser lithotripsy to extract stones from patients' kidneys, allowing physicians to completely remove stone fragments. Independent irrigation and aspiration channels ensure continuous flow. Four angled nozzles liquefy fragments for effective removal. Dynamic aspiration removes dust during lithotripsy and removes fragments after lithotripsy. The CVAC system demonstrated safety and superior stone removal in the landmark ASPIRE study.
Calyxo has developed the CVAC surgical system for kidney stone removal and the corresponding procedure called SURE. The company's device utilizes irrigation and vacuum aspiration during and after laser lithotripsy to extract stones from patients' kidneys, allowing physicians to completely remove stone fragments. Independent irrigation and aspiration channels ensure continuous flow. Four angled nozzles liquefy fragments for effective removal. Dynamic aspiration removes dust during lithotripsy and removes fragments after lithotripsy. The CVAC system demonstrated safety and superior stone removal in the landmark ASPIRE study.
6
Country: Israel | Funding: $274M
Nanox Medical develops and manufactures radiographic devices enabling lower radiation dose, higher image resolution and high degree of automation. The company has developed secondary fluorescence technology, which offers significant advantages over traditional Coolidge tubes. Its flagship device - miniC - is a multifunctional, battery-operated, miniature C-arm X-ray system. It provides images and video for orthopedic surgeries, pediatric surgeries and clinical diagnostics. Nanox also produces miniDR-85 - a portable X-ray unit powered by a 60V lithium battery. It is used for diagnostic imaging in medical facilities and emergency situations.
Nanox Medical develops and manufactures radiographic devices enabling lower radiation dose, higher image resolution and high degree of automation. The company has developed secondary fluorescence technology, which offers significant advantages over traditional Coolidge tubes. Its flagship device - miniC - is a multifunctional, battery-operated, miniature C-arm X-ray system. It provides images and video for orthopedic surgeries, pediatric surgeries and clinical diagnostics. Nanox also produces miniDR-85 - a portable X-ray unit powered by a 60V lithium battery. It is used for diagnostic imaging in medical facilities and emergency situations.
7
Country: Israel | Funding: $190M
ForSight Robotics created surgical platform designed specifically for ophthalmological (eye) surgeries — a category requiring a great deal of precision.
ForSight Robotics created surgical platform designed specifically for ophthalmological (eye) surgeries — a category requiring a great deal of precision.
8
Country: USA | Funding: $57.8M
Luminai offers an AI platform aimed at helping ease operations within health systems, including moving data between disconnected systems, easing revenue cycle and billing workflows, assisting with prior authorizations and insurance paperwork, and processing claims, forms and eligibility checks.
Luminai offers an AI platform aimed at helping ease operations within health systems, including moving data between disconnected systems, easing revenue cycle and billing workflows, assisting with prior authorizations and insurance paperwork, and processing claims, forms and eligibility checks.
9
Country: USA | Funding: $1.2B
Vir Biotechnology develops immunotherapeutics for the treatment and prevention of infectious diseases, including Flu and Covid19. Its next-generation antibody platform and PRO-XTEN protease-release masking technology are designed to treat infectious diseases and cancer, respectively. The company uses the dAIsY (Data Structure and Antibody AI) platform to design and optimize drug candidates, modulating interactions with the immune system and improving key characteristics that help us create more effective drugs faster. Vir is advancing several candidates for the treatment of hepatitis delta, solid tumors and HIV.
Vir Biotechnology develops immunotherapeutics for the treatment and prevention of infectious diseases, including Flu and Covid19. Its next-generation antibody platform and PRO-XTEN protease-release masking technology are designed to treat infectious diseases and cancer, respectively. The company uses the dAIsY (Data Structure and Antibody AI) platform to design and optimize drug candidates, modulating interactions with the immune system and improving key characteristics that help us create more effective drugs faster. Vir is advancing several candidates for the treatment of hepatitis delta, solid tumors and HIV.
10
Country: USA | Funding: $2.4B
Arrowhead Research has created the Arrowhead TRiM drug discovery and development platform that utilizes a suite of RNA interference (RNAi) delivery technologies, chemistry, structures, and manufacturing technologies. REDEMPLO (plozasiran) is the company's lead (FDA-approved) siRNA-based drug used to significantly lower triglyceride levels in adults with familial chylomicronemia syndrome (FCS). Arrowhead is also conducting clinical trials for drugs against coronary artery disease, atherosclerotic cardiovascular disease, obesity, COPD, idiopathic pulmonary fibrosis, Alzheimer's disease, Huntington's disease, alpha-1 antitrypsin deficiency and hepatitis B.
Arrowhead Research has created the Arrowhead TRiM drug discovery and development platform that utilizes a suite of RNA interference (RNAi) delivery technologies, chemistry, structures, and manufacturing technologies. REDEMPLO (plozasiran) is the company's lead (FDA-approved) siRNA-based drug used to significantly lower triglyceride levels in adults with familial chylomicronemia syndrome (FCS). Arrowhead is also conducting clinical trials for drugs against coronary artery disease, atherosclerotic cardiovascular disease, obesity, COPD, idiopathic pulmonary fibrosis, Alzheimer's disease, Huntington's disease, alpha-1 antitrypsin deficiency and hepatitis B.
